Close Menu

NEW YORK – Genentech said on Wednesday that its supplemental Biologics License Application for atezolizumab (Tecentriq) was accepted by the US Food and Drug Administration and granted priority review.

The company is pursuing approval for the drug as a first-line, monotherapy option for advanced non-small cell lung cancer patients with high PD-L1 expression, and who don't harbor EGFR or ALK mutations. It expects to hear back from the FDA on its application by mid-June.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.